Known targets — ChEMBL curated mechanism
GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHMGCRMMP1MMP13MMP7MMP8PTGS1PTGS2ileSpolrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.70 |
| ▸ | CES1 | P23141 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.70 |
| ▸ | ERCC5 | P28715 | 4/20 | 0.65 |
| ▸ | FEN1 | P39748 | 4/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | PLOD2 | O00469 | 2/20 | 0.55 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Potassium Ion SCHEMBL14935473 | 0.95 | KMT2A (0.70) | KMT2AMEN1CYP3A4HPGDMAPK1 | |
| Silver SCHEMBL527868 | 0.95 | KMT2A (0.70) | KMT2AMEN1CYP3A4HPGDMAPK1 | |
| SCHEMBL5142646 | 0.95 | KMT2A (0.70) | KMT2AMEN1CYP3A4HPGDMAPK1 | |
| SCHEMBL28519783 | 0.95 | KMT2A (0.70) | KMT2AMEN1CYP3A4HPGDMAPK1 | |
| SCHEMBL5144868 | 0.95 | KMT2A (0.70) | KMT2AMEN1CYP3A4HPGDMAPK1 | |
| SCHEMBL440631 | 0.95 | KMT2A (0.70) | KMT2AMEN1CYP3A4HPGDMAPK1 | |
| SCHEMBL7860529 | 0.85 | KMT2A (0.61) | KMT2AMEN1CYP3A4HPGDMAPK1 | |
| SCHEMBL9648913 | 0.83 | ERCC5 (0.82) | KMT2AMEN1CYP3A4HPGDMAPK1 | |
| Dibenzoylmethane SCHEMBL39582 | 0.83 | MEN1 (1.00) | KMT2AMEN1CYP3A4HPGDMAPK1 | |
| Dibenzoylmethane SCHEMBL10356288 | 0.83 | MEN1 (1.00) | KMT2AMEN1CYP3A4HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065179-A1 | PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY | YKI, Ytemiska Institutet AB (SE) | 2012-03-15 | — | — | US | disclosed |
| EP-2419398-A1 | A PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY | YKI, Ytkemiska Institutet AB (SE) | 2012-02-22 | — | — | EP | disclosed |
| WO-2010120232-A1 | A PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY | YKI, YTKEMISKA INSTITUTET AB (SE) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065179-A1 | PRODRUG COMPRISING BETA-KETO CARBOXYLIC ACID, BETA-KETO CARBOXYLIC ACID SALT OR BETA-KETO CARBOXYLIC ACID ESTER FOR DRUG DELIVERY | BCKDK, KHK, CA7 | KMT2A 1238/4885MEN1 2158/4885CYP3A4 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.